LISATA THERAPEUTICS, INC. — Director's Dealing 2016

Oct 12, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Caladrius Biosciences, Inc. (CLBS)
CIK: 0000320017
Period of Report: 2016-10-10

Reporting Person: BROWN GREGORY B (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-10-10	Common Stock	A	2500	—	Acquired	2500	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-10-10	Stock Option	$4.66	A	4150	Acquired	2026-10-10	Common Stock (4150)	Direct

Footnotes

F1: This grant was made in connection with the Reporting Person's appointment to the Issuer's board of directors, audit committee and nominating and corporate governance committee.

F2: Represents 2,500 shares of restricted stock that will vest in equal annual installments over a three-year period, commencing on the first anniversary of the grant date.

F3: The stock options vest in equal annual installments over a three-year period, commencing on the first anniversary of the grant date.